Education

Biography

Dr. Charles L Shapiro moved to Mt Sinai in October 2014 and currently is a Professor of Medicine in the Division of Hematology/Oncology, Director of Translational Breast Cancer Research for the Mt Sinai Health System, and Director of Cancer Survivorship for the Mt Sinai Health System. He is nationally known as clinical trialist emphasizing the testing of novel therapeutics in early phase trials with correlative studies. Also, he is also nationally recognized for his work in survivorship, particularly how breast cancer treatments impact bone. He served as the American Society of Clinical Oncology (ASCO) Chairman of the Survivorship Committee 2014-15. He have 154 peer-reviewed publications and over 150 invited presentations, book chapters, and abstracts.

Research Interest

• Breast cancer survivorship
• MicroRNA profiling of triple negative breast cancers

Scientific Activities:

Teaching Experience:

Professional Activities:

National

Honors & Awards

Publications

1. Wu L, deBruin A, Wang H, Simmons T, Cleghorn W, Goldenberg L, Sites E, Sandy A, Trimboli A, Fernandez S, Eng C, Shapiro CL, Leone G. Selective Roles of E2fs for ErbB2-and Myc-mediated Mammary Tumorigenesis. Oncogene. 2015; 34: 119-28. *Data acquisition. Data analysis and interpretation. Drafting or revising critically important intellectual content.
2. Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, Janni W, Rack B, Ekici AB, Slamon DJ, Konstantopoulou I, Fostira F, Vratimos A, Fountzilas G, Pelttari LM, Tapper WJ, Durcan L, Cross SS, Pilarski R, Shapiro CL, Klemp J, Yao S, Garber J, Cox A, Brauch H, Ambrosone  C, Nevanlinna H, Yannoukakos D, Slager SL, Vachon CM, Eccles DM, Fasching PA. Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. J Clin Oncol. 2015; 33: 304-11. *Data acquisition
3. Volinia S, Nuovo G, Drusco A, Costinean S, Abujarour R, Desponts C, Garofalo M, Baffa R, Aeqilan R, Maharry K, Garzon ME, Di Leva G, Gasparini P, Dama P, Marchesini J, Galasso M, Manfrini M, Zerbinati C, Corrà F, Wise T, Wojcik SE, Previati M, Pichiorri F, Zanesi N, Alder H, Palatini J, Huebner KF, Shapiro CL, Negrini M, Vecchione A, Rosenberg AL, Croce CM. Pluripotent Stem Cell miRNAs and Metastasis in Invasive Breast Cancer. J Natl Cancer Inst. 2014; 106: 2 *Data acquisition
4. Ko NY, Darnell JS, Calhoun E, Freund KM, Wells KJ, Shapiro CL, Dudley DJ, Patierno SR, Fiscella K, Raich P, Battaglia TA. Can patient navigation improve receipt of recommended breast cancer care? Evidence from the National Patient Navigation Research Program. J Clin Oncol. 2014; 32: 2758-64. Drafting or revising critically important intellectual content, data acquisition.
5. Mathsyaraja H, Thies K, Taffany DA, Deighan C, Liu T, Yu L, Fernandez SA, Shapiro CL, Otero J, Timmers C, Lustberg MB, Chalmers J, Leone G, Ostrowski MC. CSF1-ETS2-induced micro RNA in myeloid cells promote metastatic tumor growth. Oncogene. 2015; 34: 3651-61 *Data acquisition
6. Berger M, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro CL, Lustberg M. Stopping  Paclitaxel Premedication After Two Doses in Patients Not Experiencing a Previous Infusion Hypersensitivity Reaction. Supportive Care in Cancer. 2015; 23: 2019-24 Data acquisition. Data analysis and interpretation. Drafting or revising critically important intellectual content
7. Hicks M, Macrae ER, Abdel-Rasoul M, Layman R, Friedman S, Querry J, Lustberg MB, Ramaswamy B, Mrozek E, Shapiro CL, Wesolowski R. Neoadjuvant dual HER2 targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2 positive breast cancer. The  Oncologist 2015; 20: 337-43 *Drafting or revising critically important intellectual content, data acquisition.
8. Oostra D, Lustberg MB, Reinbolt RE, Pan X, Wesolowski R, Shapiro CL. Association of Osteoprotegerin and Bone Loss after Adjuvant Chemotherapy in Early-Stage Breast Cancer.  Molecular and Cellular Endocrinology 2015; 402: 51-6* Conception and design of study, Data acquisition, Data analysis and interpretation, Drafting or revising critically important intellectual content
9. Nasser MW, Wani NA, Ahirwar DK, Powell CA, Ravi J, Elbaz M, Zhao H, Padilla L, Zhang X, Shilo K, Ostrowski M, Shapiro CL, Carson WE, Ganju RK.  RAGE Mediates S100A7-Induced Breast Cancer Growth and Metastasis by Modulating the Tumor Microenvironment.  Cancer Research. 2015; 75: 974-85*Data Acquisition.
10. Powell C, Nasser MW, Zhao H, Wochna JC, Zhang X, Shapiro CL, Shilo K, Ganju R. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.  Oncotarget 2015; 6: 6373-85.
11. Caserta E, Egribovitz O Shapiro CL, Ostrowski, MC, Leone G. Noncatalytic PTEN missense mutation predisposes to organ selective cancer development in vivo.  Gene Dev 2015; 29: 1707-20 *Data Acquisition
12. Hsu EC, Kulp SK, Huang HL et.al.Shapiro CL, Chen CS. Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating gamma-Secretase-Mediated Notch1 Activation in Caveolae. Neoplasia 2015; 17: 4976-508 *Data analysis and interpretation. Drafting or revising critically important intellectual content.
13. Lester J, Crosthwaite K, Stout R, Jones, R. N. Holloman C, Shapiro CL, Andersen, BL. Oncol Nurs. Forum 2015; 42: e17-23. *Conception and design of study, Data acquisition, Data analysis and interpretation, Drafting or revising critically important intellectual content
14. Smith EM, Pang H, Ye C.et.al. Shapiro CL Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomized controlled trial - CALGB/alliance 170601 European J Cancer Care 2015, ISSN 1365-2354 Data analysis and interpretation, Drafting or revising critically important intellectual content
15. Shapiro CL, Jacobsen PB, Henderson T, et.al.  ASCO Core Curriculum for Cancer Survivorship Education J Oncology Practice, 2016; 12: 145, 3108-17 *Conception and design of study, Data acquisition, Data analysis and interpretation, Drafting or revising critically important intellectual content
16. Hsu EC, Kulp SK, Huang, HL, et.al. Shapiro CL, Chen CS Integrin-linked kinase as a novel molecular switch of the IL-6-NF-kappaB signaling loop in breast cancer.  Carcinogenesis 2016; 37: 430-42. *Conception and design of study, Drafting or revising critically important intellectual content.
17. Bickel K, McNiff K, Buss MK, Kamal A, Lupu D, Abernethy A, Broder MS, Shapiro CL, Acheson AK, Malin J, Evans T, and Krzyzanowska MK. Defining High-Quality Palliative Care in Oncology Practice: ASCO/AAHPM Guidance Statement. J Oncology Practice 2016; 12: e828-38* Conception and design of study, Data analysis and interpretation, Drafting or revising critically important intellectual content
18. Reinbolt, RE, Patel, R. Pan X, Timmers CD, Pilarski R, Shapiro, CL, Lustberg, MB. Risk factors for anthrax cycline-associated cardio toxicity. Support Care Cancer 2016; 5: 2173-80*Conception and design of study, Data analysis and interpretation, Drafting or revising critically important intellectual content
19. Himmelstein, AL, Foster, JC, Khatcherseeian, JL, …… Shapiro, CL. Effect of Longer-Interval vs. Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 2017; 317: 48-58 *Conception and design of study, Data analysis and interpretation, Drafting or revising critically important intellectual content
20. Levis, BE, Binkley, PJ, Shapiro, CL. Cardio-Oncology Recommendations: What is the Evidence and What are the Potential Harms? Lancet Oncology in press 2017.*Conception and design of study, Data analysis and interpretation, Drafting or revising critically important intellectual content